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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Brazilian Portuguese 
language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre 
was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients 
seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical valida-
tion phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/
ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity 
(convergent and discriminant validity). A total of 231 JIA patients (14.7% systemic, 43.3% oligoarticular, 22.5% RF nega-
tive polyarthritis, 19.5% other categories) and 72 healthy children, were enrolled in three centres. The JAMAR components 
discriminated well healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. 
In conclusion, the Brazilian Portuguese version of the JAMAR is a valid tool for the assessment of children with JIA and is 
suitable for use both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally 
adapt and validate the Brazilian Portuguese parent, child/
adult version of the Juvenile Arthritis Multidimensional 
Assessment Report (JAMAR) [1] in patients with juvenile 
idiopathic arthritis (JIA). The JAMAR assesses the most 
relevant parent/patient reported outcomes in JIA, includ-
ing overall well-being, functional status, health related 
quality of life (HRQoL), pain, morning stiffness, disease 
activity/status/course, articular and extra-articular involve-
ment, drug-related side effects/compliance and satisfaction 
with illness outcome.
This project was part of a larger multinational study 
conducted by the Paediatric Rheumatology International 
Trials Organisation (PRINTO) [2] aimed to evaluate the 
Epidemiology, Outcome and Treatment of Childhood 
Arthritis (EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adap-
tation and validation of the parent and patient versions of 
the JAMAR in the Brazilian Portuguese language.
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Materials and methods
The methodology employed has been described in detail 
in the introductory paper of the supplement [4]. In brief, 
it was a cross-sectional study of JIA children, classified 
according to the ILAR criteria [5, 6] and enrolled from 
May 2012 to May 2015. Children were recruited after 
Ethics Committee approval and consent from at least one 
parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task 
is scored as follows: 0 = without difficulty, 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF-HW) and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10];
 2. rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11];
 3. assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. assessment of morning stiffness (present/absent);
 5. assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. rating of the level of disease activity on a 21-circle 
VAS;
 7. rating of disease status at the time of the visit (categori-
cal scale);
 8. rating of disease course from previous visit (categori-
cal scale);
 9. checklist of the medications the patient is taking (list 
of choices);
 10. checklist of side effects of medications;
 11. report of difficulties with medication administration 
(list of items);
 12. report of school/university/work problems caused by 
the disease (list of items);
 13. assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (five 
items each) and a total score.The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not appli-
cable’ column was included in the parent version of 
the questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. a question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of at least ten JIA 
parents and ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption [mean and standard deviation (SD) equivalence]; 
the second Likert assumption or equal items-scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the 6 JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
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Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18].
Quantitative data were reported as medians with first and 
third quartiles and categorical data as absolute frequencies 
and percentages.
The complete Brazilian Portuguese parent and patient 
versions of the JAMAR are available upon request to 
PRINTO.
Results
Cross cultural adaptation
The Brazilian Portuguese JAMAR was cross-culturally 
adapted from the British English version with three for-
ward and two backward translations with a concordance for 
115/123 (93.5%) translations lines for the parent version and 
116/120 (96.7%) lines for the child version.
In the probe technique analysis, 120/123 (97.6%) lines 
of the parent version of the JAMAR were understood by 
at least 80% of the 10 parents tested (median 100%; range 
70–100%) and 117/120 (97.5%) lines of the patient version 
of the JAMAR were understood by at least 80% of the chil-
dren (median 100%; range 70–100%). Lines 52, 53, and 77 
of the parent version of the JAMAR and lines 50, 51, and 
75 were modified according to parents’ and patients’ sug-
gestions, respectively.
Demographic and clinical characteristics 
of the subjects
A total of 231 JIA patients and 72 healthy children (total 
of 303 subjects), were enrolled at three paediatric rheuma-
tology centres. In the 231 JIA subjects, the JIA categories 
were 14.7% systemic arthritis, 43.3% oligoarthritis, 22.5% 
RF negative polyarthritis, 4.8% RF positive polyarthritis, 
1.7% psoriatic arthritis, 10.8% enthesitis related arthritis and 
2.2% undifferentiated arthritis (Table 1).
A total of 296/303 (97.7%) subjects had the parent ver-
sion of the JAMAR completed by a parent (226 from parents 
of JIA patients and 70 from parents of healthy children). The 
JAMAR was completed by 256/296 (86.5%) mothers and 
40/296 (13.5%) fathers. The child version of the JAMAR 
was completed by 265/303 (87.5%) children age 6.0 years 
or older. Also patients younger than 7 years old, capable to 
assess their personal condition and able to read and write, 
were asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including the 
scores [median (first–third quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The fol-
lowing “Results” section, unless otherwise specified, refers 
mainly to the parent’s version findings.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers and input null values. The response 
pattern for both PF and HRQoL was positively skewed 
toward normal functional ability and normal HRQoL. All 
response choices were used for the different HRQoL items 
except for item 8, whereas a reduced number of response 
choices was used for PF item 15.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items 
(data not shown). The median number of items marked as 
not applicable was 1% (0–1%) for the PF and 4% (3–6%) for 
the HRQoL.
Floor and ceiling effect
The median floor effect was 87.2% (80.5–88.5%) for the PF 
items, 72.6% (65.0–74.3%) for the HRQoL PhH items, and 
66.8% (64.2–70.8%) for the HRQoL PsH items. The median 
ceiling effect was 0.9% (0.9–2.7%) for the PF items, 4.0% 
(2.7–4.0%) for the HRQoL PhH items, and 3.1% (2.2–3.5%) 
for the HRQoL PsH items. The median floor effect was 
57.5% for the pain VAS, 51.3% for the disease activity VAS 
and 55.7% for the well-being VAS. The median ceiling effect 
was 1.8% for the pain VAS, 0.4% for the disease activity 
VAS and 1.3% for the well-being VAS.
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Table 1  Descriptive statistics (medians first third quartiles or absolute frequencies and %) for the 231 JIA patients
Systemic Oligoar-
thritis
RF − poly-
arthritis
RF + poly-
arthritis
Psoriatic 
arthritis
Enthesitis 
related 
arthritis
Undif-
ferentiated 
arthritis
All JIA 
patients
Healthy
N = 34 N = 100 N = 52 N = 11 N = 4 N = 25 N = 5 N = 231 N = 72
Female 18 (52.9%) 72 (72%) 36 (69.2%) 8 (72.7%) 3 (75%) 2 (8%) 2 (40%) 141 (61%)# 45 (62.5%)
Age at visit 13.5 (10.3–
16.5)
12 (9.1–15) 11.5 
(8.7–14.6)
14.6 (12.8–
17.3)
13.2 (11.6–
14.7)
14.7 (12.6–
17.1)
8.9 (7–13.9) 13.1 (9.8–
15.3)*
12.1 
(9.4–14.6)
Age at onset 7.6 (4.3–
11.6)
5.5 (2.7–9.7) 5.3 (2.6–9.1) 8.9 (6.9–
12.6)
8.4 (6.9–
10.8)
8.7 (6–9.9) 6.6 (3.7–6.7) 6.4 (3–9.8)*
Disease 
duration
3.4 (1.4–7.7) 4.9 (2.3–7.9) 4.5 (1.7–8.6) 4.7 (2.2–7.6) 4.7 
(2.3–6.3)
5.3 (4.1–9.2) 3.2 (2.1–3.3) 4.7 
(2.1–8.1)
ESR 13 (8–33) 9 (4–23) 14 (6–23) 22.5 (15–40) 11 (6–15) 10 (4–20) 10 (7–13) 11 (5–23)
MD VAS 
(0–10 cm)
0 (0–4) 0 (0–1) 1 (0–4) 4 (1.5–7) 0 (0–2) 0 (0–2) 0 (0–0) 0 (0–2)*
No. swollen 
joints
0 (0–2) 0 (0–1) 1 (0–4) 2 (0–7) 1 (0–3) 0 (0–2) 0 (0–0) 0 (0–2)*
No. joints 
with pain
0 (0–2) 0 (0–0) 1 (0–3) 1 (0–5) 0 (0–1) 0 (0–0) 0 (0–0) 0 (0–1)#
No. joints 
with LOM
0 (0–5) 0 (0–0) 1 (0–7) 4 (2–20) 0.5 (0–2.5) 0 (0–1) 0 (0–0) 0 (0–2)#
No. active 
joints
0 (0–2) 0 (0–1) 2 (0–4.5) 4 (1–7) 1 (0–3) 0 (0–2) 0 (0–0) 0 (0–2)#
Active 
systemic 
features
3 (8.8%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (1.3%)*
ANA status 1 (2.9%) 20 (20%) 7 (13.5%) 1 (9.1%) 0 (0%) 0 (0%) 1 (20%) 30 (13%)
Uveitis 1 (2.9%) 15/99 
(15.2%)
2 (3.8%) 0 (0%) 0 (0%) 1 (4%) 0 (0%) 19/229 
(8.3%)
PF Total 
Score
2 (0–7) 0 (0–3) 2 (0–5) 6 (0–12) 1.5 
(0.5–2.5)
0 (0–3) 1 (0–1) 1 (0–4) 0 (0–0)#
Pain VAS 0.3 (0–4) 0 (0–1.3) 1 (0–2.5) 0.5 (0–3.5) 0 (0–0.5) 0 (0–4) 0 (0–0) 0 (0–2) 0 (0–0)#
Disease 
Activity 
VAS
0 (0–4.5) 0 (0–1) 1 (0–5) 1.5 (0–3.5) 0.5 (0–1) 0 (0–4) 0 (0–0) 0 (0–3)
Well-being 
VAS
0 (0–4) 0 (0–1.3) 0.5 (0–2) 2 (0–7.5) 0.3 (0–1) 0 (0–4.5) 0 (0–0) 0 (0–2)
HRQoL PhH 1.5 (0–5) 1 (0–2) 1 (0–4) 3 (0–6) 0 (0–0.5) 1 (0–4) 0 (0–0) 1 (0–3) 0 (0–0)#
HRQoL PsH 1 (0–4) 1 (0–3) 1 (0–4) 2 (0–3) 5 (2–6.5) 1 (0–3) 1 (1–2) 1 (0–3) 0 (0–1)**
HRQoL 
Total Score
3.5 (0–10) 2 (0–5) 3 (1–7) 3 (1–11) 5 (2–7) 3 (0–6) 1 (1–3) 3 (0–6) 0 (0–2)#
Pain/swell. 
in > 1 joint
16 (47.1%) 31/96 
(32.3%)
31/51 
(60.8%)
8 (72.7%) 0 (0%) 10 (40%) 0 (0%) 96/226 
(42.5%)
5/70 (7.1%)#
Morning 
stiff. > 
15 min
6 (17.6%) 7/96 (7.3%) 9/51 (17.6%) 2 (18.2%) 0 (0%) 3 (12%) 0 (0%) 27/226 
(11.9%)
0 (0%)*
Subjective 
remission
13 (38.2%) 29/96 
(30.2%)
29/51 
(56.9%)
8 (72.7%) 1 (25%) 11 (44%) 0 (0%) 91/226 
(40.3%)
In treatment 23 (67.6%) 56/96 
(58.3%)
44/51 
(86.3%)
10 (90.9%) 3 (75%) 19 (76%) 3 (60%) 158/226 
(69.9%)
Reporting 
side effects
8/23 (34.8%) 10/56 
(17.9%)
12/44 
(27.3%)
0 (0%) 1/3 (33.3%) 1/19 (5.3%) 1/3 (33.3%) 33/158 
(20.9%)
Taking 
medication 
regularly
23/23 
(100%)
52/56 
(92.9%)
40/44 
(90.9%)
9/10 (90%) 3/3 (100%) 16/19 
(84.2%)
3/3 (100%) 146/158 
(92.4%)
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Equal items‑scale correlations (second Likert 
assumption)
Pearson items-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 87% of the PF 
items, with the exception of PF items 13 and 15, and for 80% 
of the HRQoL items, with the exception of items 8 and 9.
Items internal consistency (third Likert assumption)
Pearson items-scale correlations were ≥ 0.4 for 100% of 
items of the PF and 100% of items of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.89 for PF-LL, 0.89 for PF-HW, 0.83 
for PF-US. Cronbach’s alpha was 0.85 for HRQoL-PhH and 
0.79 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 15 JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after 
a median of 7 days (7–10 days). The intraclass correlation 
coefficients (ICC) for the PF total score showed an almost 
perfect reproducibility (ICC 0.94). The ICC for the HRQoL 
PhH and for the HRQoL PsH showed an almost perfect 
reproducibility (ICC 0.92 and ICC 0.87, respectively).
Convergent validity
The Spearman correlation of the PF total score with 
the JIA core set of outcome variables ranged from 0.4 
to 0.5 (median 0.4). The PF total score best correlation 
was observed with the parent assessment of pain (r = 0.6, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged 
from 0.4 to 0.6 (median 0.4), whereas for the PsH ranged 
from 0.2 to 0.4 (median 0.2). The PhH showed the best 
correlation with the parent’s assessment of pain (r = 0.7, 
p < 0.001) and the PsH with the parent global assess-
ment of well-being (r = 0.4, p < 0.001). The median cor-
relations between the pain VAS, the well-being VAS, and 
the disease activity VAS and the physician-centered and 
laboratory measures were 0.4 (0.3–0.4), 0.4 (0.3–0.5), 0.4 
(0.4–0.5), respectively.
Discussion
In this study, the Brazilian Portuguese version of the 
JAMAR was cross-culturally adapted from the original 
standard English version with 2 forward and 2 backward 
translations. According to the results of the validation 
analysis, the Brazilian Portuguese parent and patient 
versions of the JAMAR have satisfactory psychometric 
Data related to the JAMAR refers to the 226 JIA patients and to the 70 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD Medical Doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA Anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health related quality of life (total score ranges from 0 to 30), PhH Physical Health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refers to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Table 1  (continued)
Systemic Oligoar-
thritis
RF − poly-
arthritis
RF + poly-
arthritis
Psoriatic 
arthritis
Enthesitis 
related 
arthritis
Undif-
ferentiated 
arthritis
All JIA 
patients
Healthy
N = 34 N = 100 N = 52 N = 11 N = 4 N = 25 N = 5 N = 231 N = 72
With 
problems 
attending 
school
2/19 (10.5%) 5/77 (6.5%) 1/34 (2.9%) 0 (0%) 0 (0%) 2/18 (11.1%) 1 (20%) 11/163 
(6.7%)
0 (0%)*
Satisfied 
with 
disease 
outcome
27 (79.4%) 83/96 
(86.5%)
42/51 
(82.4%)
7 (63.6%) 3 (75%) 22 (88%) 5 (100%) 189/226 
(83.6%)
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properties. The disease-specific components of the ques-
tionnaire discriminated well between patients with JIA and 
healthy controls. Psychometric performance was good for 
all the JAMAR domains and the overall internal consist-
ency was equally good for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters were moderate.
The results obtained for the parent version of the 
JAMAR are very similar to those obtained for the child 
version, which suggests that children are equally reliable 
proxy reporters of their disease and health status as their 
parents.
The JAMAR is aimed to evaluate the side effects of 
medications and school attendance, which are other dimen-
sions of daily life that were not previously considered by 
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 226/296 Child N = 203/265
Missing values (first–third quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 87.2% 90.1%
 HRQoL PhH 72.6% 75.9%
 HRQoL PsH 66.8% 70.0%
 Pain VAS 57.5% 53.2%
 Disease activity VAS 51.3% 48.3%
 Well-being VAS 55.7% 59.6%
Ceiling effect, median
 PF 0.9% 0.5%
 HRQoL PhH 4.0% 2.0%
 HRQoL PsH 3.1% 3.4%
 Pain VAS 1.8% 1.5%
 Disease activity VAS 0.4% 1.5%
 Well-being VAS 1.3% 1.0%
Items with equivalent item-scale correlation 87% for PF, 80% for HRQoL 93% for PF, 100% for HRQoL
Items with items-scale correlation ≥ 0.4 100% for PF, 100% for HRQoL 93% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.89 0.86
 PF-HW 0.89 0.87
 PF-US 0.83 0.79
 HRQoL-PhH 0.85 0.83
 HRQoL-PsH 0.79 0.78
Items with item-scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.94 0.95
 HRQoL-PhH 0.92 0.89
 HRQoL-PsH 0.87 0.81
Spearman correlation with JIA core-set variables, median
 PF 0.4 0.4
 HRQoL PhH 0.4 0.5
 HRQoL PsH 0.2 0.3
 Pain VAS 0.4 0.3
 Disease activity VAS 0.4 0.3
 Well-being VAS 0.4 0.4
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other HRQoL tools. This may provide useful information 
for intervention and follow-up in health care.
In conclusion, the Brazilian Portuguese version of the 
JAMAR was found to have satisfactory psychometric prop-
erties and it is, thus, a reliable and valid tool for the multi-
dimensional assessment of children with JIA.
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